Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease. (ELECT-RO)

• ClinicalTrials.gov Identifier: NCT03695874
• Recruitment Status: Completed
• First Posted: October 4, 2018
• Last Update Posted: February 8, 2021
• Sponsor: Hospices Civils de Lyon
• Information provided by (Responsible Party): Hospices Civils de Lyon

Study Description

Brief Summary:

Hereditary Haemorrhagic Telangiectasia (HHT) is a rare inherited genetic disease of autosomal dominant inheritance with a prevalence of 1/6000. It is manifested by haemorrhages, mucocutaneous telangiectasias and visceral arteriovenous malformations. These symptoms significantly affect the daily lives of patients, their social relationships and their working lives.

HAS (Haute Autorité de Santé) national recommendations focus on assessing and improving the quality of life (QOL) of patients. Many scales for measuring QOL exist but they are most often general and therefore have the disadvantage of not taking into account the particularities of pathologies and their symptoms and do not allow to have a precise vision of their impact on QOL.

It is important to be able to evaluate this impact, to determine its nature and to quantify it so that health professional can adapt their proposal for the management of HHT patients. And only the development of a specific and validated QOL measurement scale will allow them to access this information.

The aim of this study is to develop a scale of measurement of quality of life in HHT disease and to validate it, a scale specific to HHT, simple and fast to fill by the patients themselves.

Condition or disease	Intervention/treatment
Hereditary Hemorrhagic Telangiectasia	Other: Phase 1 : fill out 1 scale; Other: Phase 2 : fill out 1 scale and 4 questionnaires

Study Design

• Study Type: Observational
• Actual Enrollment: 643 participants
• Observational Model: Other
• Time Perspective: Prospective
• Official Title: Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease.
• Actual Study Start Date: January 28, 2019
• Actual Primary Completion Date: December 28, 2020
• Actual Study Completion Date: December 28, 2020

Groups and Cohorts

Group/Cohort	Intervention/treatment
Phase 1: statistical purification; 400 Hereditary Haemorrhagic Telangiectasia patients: over 18 years; able to read French; with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology; who received the information and did not object to participate in the study	Other: Phase 1 : fill out 1 scale; Patients will be asked to complete questionnaires. Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items). Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires.
Phase 2: statistical validation; 200 Hereditary Haemorrhagic Telangiectasia patients: over 18 years; able to read French; with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology; who received the information and did not object to participate in the study	Other: Phase 2 : fill out 1 scale and 4 questionnaires; Patients will be asked to complete questionnaires. Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale. Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires.

Outcome Measures

Primary Outcome Measures :

1. Validity of the factor structure of the developed measurement scale. [ Time Frame: 1 hour ]
   Saturation coefficients of the exploratory factor analysis observed on the sample of 400 participants, confirmatory factor analysis (CFA) adjustment indices on the sample of 200 participants, and factorial weights observed on the AFC will be combined to evaluate the structural validity of the measurement scale.
2. Validity of the reliability of the developed measurement scale. [ Time Frame: 1 hour ]
   Cronbach alphas coefficients, composite reliability values (rho) and percentages of extracted variance will be combined to assess the Reliability of the measurement scale.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Patients with an Hereditary Haemorrhagic Telangiectasia disease.

Criteria

Inclusion Criteria:

• over 18 years
• able to read French
• with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology
• who received the information and did not object to participate in the study

Exclusion Criteria:

• None

Contacts and Locations

Locations

France

Centre de Référence pour la Maladie de Rendu-Osler - Service de Génétique Clinique - HOSPICES CIVILS DE LYON - Groupement Hospitalier Est

Bron, France, 69677

Sponsors and Collaborators

Hospices Civils de Lyon

More Information

• Responsible Party: Hospices Civils de Lyon
• ClinicalTrials.gov Identifier: NCT03695874
• Other Study ID Numbers: 69HCL18_0543
• First Posted: October 4, 2018
• Last Update Posted: February 8, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Telangiectasis; Telangiectasia, Hereditary Hemorrhagic; Vascular Diseases; Cardiovascular Diseases; Hemostatic Disorders; Hemorrhagic Disorders; Hematologic Diseases; Vascular Malformations; Cardiovascular Abnormalities; Congenital Abnormalities